CASPOFUNGIN XELLIA 50 Milligram Pdr/Conc/Soln for Infus
Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
Productkenmerken
(SPC)
12-11-2016
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CASPOFUNGIN
Beschikbaar vanaf:
Fresenius Kabi Limited
ATC-code:
J02AX04
INN (Algemene Internationale Benaming):
CASPOFUNGIN
Dosering:
50 Milligram
farmaceutische vorm:
Pdr/Conc/Soln for Infus
Prescription-type:
Product subject to prescription which may not be renewed (A)
Therapeutisch gebied:
Other mycotics for systemic use
Autorisatie-status:
Authorised
Autorisatie datum:
2016-10-28
Productkenmerken
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Caspofungin Xellia 50 mg Powder for concentrate for solution for infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 50 mg caspofungin (as acetate). The concentration of the reconstituted vial is 5.2 mg/ml.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion.
The powder is a white to off-white powder.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
•
Treatment of invasive candidiasis in adult or paediatric patients.
•
Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of
amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as
progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective
antifungal therapy.
•
Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic
adult or paediatric patients.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Caspofungin should be initiated by a physician experienced in the management of invasive fungal infections.
Posology
_Adult patients_
A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. In patients
weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section
5.2). No dosage adjustment is necessary based on gender or race (see section 5.2).
_Paediatric patients (12 months to 17 years)_
In paediatric patients (12 months to 17 years of age), dosing should be based on the patient's body surface area (see
Instructions for Use in Paediatric Patients, Mosteller
1
Formula). For all indications, a
Lees het volledige document
